Methods and compositions for controlling efficacy of rna silencing
CA 2528012 C · Owner: University Of Massachusetts · Inventors: Zamore, Phillip D.; Tang, Guiliang
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described here is a method of making an RNAi agent with enhanced efficacy the , RNAi agent , includes an antisense strand that is complementary to a target mRNA. The method includes , substituting at least one nucleotide within 5 or fewer nucleotides from the 3' end or the 5' end , of the antisense strand of the RNAi agent with a nucleotide which forms a G:U wobble base , pair with the corresponding nucleotide in a target mRNA such that efficacy is , enhanced. Also described is a method of, and corresponding use of the RNAi agent for silencing target , mRNA. Compositions comprising the RNAi agent are also described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 2, 2004 and granted November 24, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 2, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 2, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.